Design of the PERSEO Registry on the management of patients treated with oral anticoagulants and coronary stent.

Autor:	Sciahbasi A; Interventional Cardiology, Sandro Pertini Hospital, Rome., Gargiulo G; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II., Talarico GP; Interventional Cardiology, Policlinico Casilino, Rome., Cesaro A; Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano,' Caserta., Zilio F; Department of Cardiology, Santa Chiara Hospital, Trento., De Rosa S; Division of Cardiology, Research Center for Cardiovascular Diseases, University Magna Graecia, Catanzaro., Talanas G; Clinical and Interventional Cardiology, Sassari University Hospital., Tebaldi M; Cardiovascular Institute, Azienda Ospedaliero-Universitaria di Ferrara, Cona., Andò G; Cardiology, Department of Clinical and Experimental Medicine, University of Messina., Rigattieri S; Interventional Cardiology, Sant'Andrea Hospital, Rome., Misuraca L; Cardiology Department, Misericordia Hospital, Grosseto., Cortese B; Department of Cardiology, San Carlo Clinic, Fondazione Ricerca e Innovazione Cardiovascolare Milan., Imperadore F; Cardiology, Santa Maria Hospital, Rovereto., Lucci V; Interventional Cardiology San Filippo and Nicola Hospital, Avezzano., Guiducci V; Cardiology Division Arcispedale Santa Maria Nuova, Reggio Emilia., Renda G; Department of Neuroscience, Imaging and Clinical Sciences, G. D'Annunzio University of Chieti-Pescara., Zezza L; Panico Hospital, Tricase., Versaci F; Division of Cardiology, Santa Maria Goretti Hospital, Latina., Giannico MB; Division of Cardiology, Sant'Eugenio Hospital, Rome., Caruso M; Division of Interventional Cardiology, ARNAS Civico Hospital, Palermo., Spaccarotella C; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II., Calabrò P; Division of Clinical Cardiology, A.O.R.N. 'Sant'Anna e San Sebastiano,' Caserta., Esposito G; Division of Cardiology, Department of Advanced Biomedical Sciences, University of Naples Federico II., Tarantini G; Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua Medical School, Padua., Musumeci G; Division of Cardiology, Azienda Ospedaliera Ordine Mauriziano di Torino, Turin., Rubboli A; Department of Cardiovascular Diseases-AUSL Romagna, Division of Cardiology, S. Maria delle Croci Hospital, Ravenna, Italy.
Jazyk:	angličtina
Zdroj:	Journal of cardiovascular medicine (Hagerstown, Md.) [J Cardiovasc Med (Hagerstown)] 2022 Nov 01; Vol. 23 (11), pp. 738-743. Date of Electronic Publication: 2022 Sep 07.
DOI:	10.2459/JCM.0000000000001372
Abstrakt:	Aim: Percutaneous coronary intervention with stent implantation (PCI-S) in patients requiring chronic oral anticoagulant therapy (OAC) is associated with an increased risk of bleeding and ischemic complications. Different randomized studies showed a significant advantage of a double antithrombotic therapy and superiority of direct oral anticoagulant (DOAC) compared with warfarin, but real-world data are limited. Aim is to evaluate the antithrombotic management and clinical outcome of patients with an indication for OAC who undergo PCI-S in a 'real-world' setting. Methods: The multicentre prospective observational PERSEO (PERcutaneouS coronary intErventions in patients treated with Oral anticoagulant therapy) Registry (ClinicalTrials.gov Identifier: NCT03392948) has been designed to enrol patients requiring OAC treated by PCI-S in 25 Italian centres. A target of at least 1080 patients will be followed for 1 year and data on thromboembolic and bleeding events and changes in antithrombotic therapy will be registered. The primary end point is a combined measure of efficacy and safety outcome (NACE), including major bleeding events and major adverse cardiac and cerebral events at 1-year follow-up in patients treated with DOAC (and dual or triple antiplatelet therapy) compared with the corresponding strategies with vitamin K antagonists. A secondary prespecified analysis has been defined to evaluate NACE in dual versus triple antithrombotic therapy after hospital discharge at 1-year follow-up. Conclusion: The PERSEO Registry will investigate in a 'real world' setting the safety and efficacy of DOAC versus warfarin and dual versus triple antithrombotic therapy in patients with indication for oral anticoagulant therapy who undergo PCI-S. (Copyright © 2022 Italian Federation of Cardiology - I.F.C. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu